0001493152-24-003785.txt : 20240125 0001493152-24-003785.hdr.sgml : 20240125 20240125171630 ACCESSION NUMBER: 0001493152-24-003785 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240124 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANGOCEUTICALS, INC. CENTRAL INDEX KEY: 0001938046 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 873841292 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41615 FILM NUMBER: 24563198 BUSINESS ADDRESS: STREET 1: 15110 DALLAS PKWY, SUITE 600 CITY: DALLAS STATE: TX ZIP: 75248 BUSINESS PHONE: (833) 626-4679 MAIL ADDRESS: STREET 1: 15110 DALLAS PKWY, SUITE 600 CITY: DALLAS STATE: TX ZIP: 75248 8-K 1 form8-k.htm
false 0001938046 0001938046 2024-01-24 2024-01-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): January 24, 2024

 

MANGOCEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Texas   001-41615   87-3841292

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

15110 N. Dallas Parkway, Suite 600

Dallas, Texas

   75248
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (214) 242-9619

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per Share   MGRX  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01 Other Events.

 

As previously disclosed in the Current Report on Form 8-K, filed by Mangoceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “Commission” or the “SEC”) on November 7, 2023, on November 3, 2023, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “Rule”) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the Company reported stockholders’ equity of $1,354,821, which is below the minimum stockholders’ equity required for continued listing pursuant to the Rule. Additionally, the Company does not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules.

 

Nasdaq provided the Company until December 18, 2023 to submit to Nasdaq a plan to regain compliance. We submitted the plan to regain compliance in a timely manner, and on January 24, 2024, Nasdaq advised the Company that it has determined to grant the Company an extension to regain compliance with the Rule.

 

The terms of the extension are as follows: on or before April 29, 2024, the Company must complete certain transactions described in greater detail in the compliance plan, contemplated to result in the Company increasing its stockholders’ equity to more than $2.5 million, and opt for one of the two following alternatives to evidence compliance with the Rule: Alternative 1: The Company must furnish to the SEC and Nasdaq a publicly available report (e.g., a Form 8-K) including: 1. A disclosure of Staff’s deficiency letter and the specific deficiency(ies) cited; 2. A description of the completed transaction or event that enabled the Company to satisfy the stockholders’ equity requirement for continued listing; and 3. An affirmative statement that, as of the date of the report, the Company believes it has regained compliance with the stockholders’ equity requirement based upon the specific transaction or event referenced in Step 2; or Alternative 2: The Company must furnish to the SEC and Nasdaq a publicly available report including: 1. Steps 1 & 2 set forth above; 2. A balance sheet no older than 60 days with pro forma adjustments for any significant transactions or event occurring on or before the report date; and 3. that the Company believes it satisfies the stockholders’ equity requirement as of the report date. The pro forma balance sheet must evidence compliance with the stockholders’ equity requirement.

 

Additionally, in either case the Company is required to disclose that Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic report the Company does not evidence compliance, that it may be subject to delisting.

 

Regardless of which alternative the Company chooses, if the Company fails to evidence compliance upon filing its next periodic report with the SEC following the end of such compliance period, the Company may be subject to delisting. In the event the Company does not satisfy these terms, Nasdaq will provide written notification that its securities will be delisted. At that time, the Company may appeal Nasdaq’s determination to a Hearings Panel.

 

The Company is currently evaluating various courses of action to regain compliance and is hopeful that it can regain compliance with Nasdaq’s minimum stockholders’ equity standard within the compliance period. However, there can be no assurance that the Company will be able to complete the transactions contemplated in the compliance plan, which the Company expects will allow it to regain compliance with the Rule, or that such transactions will result in the Company regaining compliance with the Rule, within the compliance period granted by Nasdaq, if at all.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MANGOCEUTICALS, INC.
     
Date: January 25, 2024 By: /s/ Jacob D. Cohen
    Jacob D. Cohen
    Chief Executive Officer

 

 

 EX-101.SCH 2 mgrx-20240124.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 mgrx-20240124_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 mgrx-20240124_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 24, 2024
Entity File Number 001-41615
Entity Registrant Name MANGOCEUTICALS, INC.
Entity Central Index Key 0001938046
Entity Tax Identification Number 87-3841292
Entity Incorporation, State or Country Code TX
Entity Address, Address Line One 15110 N. Dallas Parkway
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75248
City Area Code (214)
Local Phone Number 242-9619
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share
Trading Symbol MGRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 6 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001938046 2024-01-24 2024-01-24 iso4217:USD shares iso4217:USD shares false 0001938046 8-K 2024-01-24 MANGOCEUTICALS, INC. TX 001-41615 87-3841292 15110 N. Dallas Parkway Suite 600 Dallas TX 75248 (214) 242-9619 false false false false Common Stock, $0.0001 Par Value Per Share MGRX NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mangoceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mgrx-20240124.xsd mgrx-20240124_lab.xml mgrx-20240124_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "MGRX", "nsuri": "http://mangoceuticals.com/20240124", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mgrx-20240124.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mgrx-20240124_lab.xml" ] }, "presentationLink": { "local": [ "mgrx-20240124_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://mangoceuticals.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://mangoceuticals.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001493152-24-003785-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-003785-xbrl.zip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